MAINZ, Germany and SHANGHAI, China June 24, 2024’
BioNTech SE’ (Nasdaq: BNTX, BioNTech) and ’Duality Biologics’ (Suzhou) Co. Ltd. (DualityBio) have announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for their antibody-drug conjugate candidate, BNT324/DB-1311. This innovative candidate targets advanced/unresectable or metastatic castration-resistant prostate cancer (CRPC) in patients who have shown progression following standard systemic treatments.
BNT324/DB-1311 is a next-generation antibody-drug conjugate (ADC) that targets the transmembrane glycoprotein B7-H3. B7-H3 is an immune checkpoint protein overexpressed in various tumor types and is linked with disease progression and unfavorable prognosis. The candidate is currently under evaluation in an ongoing Phase 1/2 study (NCT05914116) focusing on advanced solid tumors.
This Fast Track designation is a significant step forward for BioNTech and DualityBio’s collaborative effort in advancing cancer immunotherapy. The designation aims to expedite the development and review processes, potentially bringing a novel treatment option for CRPC patients closer to approval and availability.
Expanding Vaccine Ecosystems in Africa’
In parallel to their cancer research, BioNTech has also made significant advancements in the global health sphere. On May 29, 2024, BioNTech announced an expanded strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). This collaboration aims to strengthen Africa’s resilience against future health emergencies by developing a sustainable and comprehensive vaccine ecosystem.
CEPI has committed up to USD $145 million to support BioNTech in establishing mRNA vaccine research and development (R&D), as well as clinical and commercial-scale manufacturing capabilities, at BioNTech’s facility in Kigali, Rwanda. This initiative is expected to bolster Africa’s preparedness for potential future epidemic and pandemic threats, contributing significantly to global health security.
Clinical Data Presentations at ASCO 2024’
Furthermore, BioNTech is set to present critical clinical data updates for several of its next-generation immunotherapy candidates at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, taking place from May 31 to June 4, 2024, in Chicago, Illinois. The presentations will highlight advancements in BioNTech’s diversified immuno-oncology pipeline, which includes CAR-T cell therapies and individualized mRNA treatment programs.
In addition to clinical trial data, BioNTech will present epidemiological and real-world data from two observational studies. These studies focus on patient populations for whom BioNTech is developing product candidates, providing valuable insights into the ongoing and future applications of their clinical programs.
Conclusion’
BioNTech’s recent milestones in both oncology and vaccine ecosystem enhancement underline the company’s commitment to advancing healthcare solutions globally. The FDA’s Fast Track designation for BNT324/DB-1311, the strategic partnership with CEPI to build Africa’s mRNA vaccine ecosystem, and the presentations of cutting-edge clinical data at ASCO 2024 collectively underscore BioNTech’s pivotal role in pioneering medical and scientific breakthroughs.
Comments